On January 5, 2026, MetaVia Inc. announced positive results from its Phase 1 clinical trial of DA-1726, a treatment for obesity. The trial involved an extended eight-week dosage with statistically significant findings.
AI Assistant
METAVIA INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.